200 Inner Belt Road
About Finch TherapeuticsFinch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable clinical outcomes, and develops therapies that deliver those microbial communities to patients. FIN-403 is both Finch’s lead clinical program and a valuable tool for its broader human-first discovery strategy.
CEO: Mark Smith
COO: Andrew Noh
CFO: Susan Clancy
Please click here for Finch job opportunities.
Please click here for clinical trial information.
8 articles with Finch Therapeutics
Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection
Designation to accelerate Finch’s efforts to provide an effective therapy for patients fighting recurrent C. difficile infection.
After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Finch Therapeutics Group, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms.
Finch Therapeutics Expands Senior Leadership Team with Appointments of Dr. Ulrich Thienel as Chief Medical Officer and Gregory Perry as Chief Financial Officer
Dr. Thienel will lead the clinical development of Finch’s Full-Spectrum Microbiota™ and Rationally-Selected Microbiota™ platforms, while Mr. Perry will provide strategic financial and operational leadership at Finch.
Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million.
Two privately-held biotechs have merged to tackle recurrent C. difficile infections.
OpenBiome Partnering With Finch Therapeutics To Enable FDA Approval Of A Fecal Transplant Treatment For Recurrent C. Difficile Infection